Lv31
248 积分 2021-01-12 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
4小时前
待确认
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
24天前
已完结
Maintenance after first-line treatment for advanced soft tissue sarcoma
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
3个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
3个月前
已完结
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
3个月前
已完结
Immunotherapies for hepatocellular carcinoma
3个月前
已完结
Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma
3个月前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
3个月前
已完结
Hallmarks of liver cancer: Therapeutic implications
3个月前
已完结
皖公网安备34019202002308
